- cafead   Nov 17, 2022 at 11:12: AM
via The U.S. regulator is asking Clovis to limit Rubraca’s use for the second-line maintenance treatment of ovarian cancer to patients whose tumors have BRCA mutations, the company said Wednesday, citing a Monday teleconference with the FDA. The drug’s current label allows it to treat patients with recurrent ovarian cancer who’ve responded to chemo regardless of their BRCA biomarker status.
article source
article source